Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform, February 27, 2020, Ingelheim, Germany and San Diego, California
Boehringer Ingelheim will work with Trutino Biosciences to access the company’s OnDemand-Cytokine™ (ODC) platform to develop new cancer immunology compounds. The partners aim to develop safer, more tolerable and more effective cytokine therapies for single agent and novel combinations with Boehringer Ingelheim’s innovative cancer vaccine, oncolytic virus, T cell engager and myeloid-targeting therapies
Ingelheim, Germany and San Diego, California – 27 February 2020 –
Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and
worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform.
Under the terms of strategic alliance, Boehringer Ingelheim gains access to Trutino’s ODC platform
technology for the generation and development of up to three new ODC candidates. This new
collaboration combines Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough
therapies for cancer patients with Trutino’s unique knowledge and expertise in increasing the safety and
efficacy of cytokine therapies
“Developing a strong and innovative cytokine therapeutic program as an additional component of our
cancer immunology portfolio, demonstrates how we are ‘Taking Cancer On,’ and provides a high
potential combination partner for our existing cancer vaccine, oncolytic virus, T cell engager and
myeloid-targeting therapeutics portfolio,” said Jonathon Sedgwick, Ph.D., Senior Vice President and
Global Head, Cancer Immunology & Immune Modulation Research at Boehringer Ingelheim. “We are
very pleased to partner with Trutino and harness the potential of their innovative scientific platform to
develop treatment breakthroughs that will transform the lives of cancer patients.”
Trutino’s ODC platform masks the activity of cytokines until they reach the tumor site and become fully
activated, sparing systemic exposure and potentially leading to a higher margin of safety and greater
efficacy than conventional cytokine treatments. Trutino will generate the new ODC molecules and carry
out preclinical validation, handing over development to Boehringer Ingelheim for late pre-clinical testing
through the rest of development.
“We are excited to embark on this partnership with Boehringer Ingelheim, a leader in cancer
immunology, to advance cytokine therapeutic options that address the unmet medical needs of patients
worldwide,” said Phillip Kim, Ph.D., MBA, Founder and CEO of Trutino Biosciences. “Boehringer
Ingelheim has a deep commitment to innovative scientific approaches and is a leader in bringing novel
cancer therapies to market. This global partnership validates the broad potential of our proprietary ODC
platform to create safer and more effective cytokine therapies that can be delivered systemically and
activated locally. Together, we can rapidly develop a new generation of cytokine therapies to address
critical unmet need in oncology.”
Trutino’s clinical potential was initially recognized by Boehringer Ingelheim through its grassroots
programs, including the ‘BI Innovation Prize’, where the ODC platform technology was an early-stage
standout in the 2019 program held in San Diego. Launched in 2015, the grassroots programs comprise
of ‘BI Office Hours,’ ‘BI Academy’ and the ‘BI Innovation Prize.’ Through Office Hours, Boehringer
Ingelheim has provided over 200 early-stage companies in the life-sciences community with mentoring
and direct access to relevant expertise and industry perspective from senior leaders within the
company. In partnership with BioLabs in Boston, New York and San Diego, Boehringer Ingelheim has
awarded numerous entrepreneurs with freelab space through the ‘Golden Ticket’ program. As a
company dedicated to improving health and quality of life, these programs give Boehringer Ingelheim
the opportunity to lend expertise to the innovation community and offer guidance around the science to
help enable ideas to deliver the next breakthroughs.
The partnership with Trutino will strengthen Boehringer Ingelheim’s next generation immune oncology
portfolio, which combines cancer vaccines, oncolytic viruses, T Cell engagers and myeloid targeting
platforms with the aim of making “cold” tumors that are invisible to the immune system “hot” to rally
the immune system against the tumor. Under the terms of the agreement, Boehringer Ingelheim will
provide an upfront payment, near-term pre-clinical milestone payments and clinical, regulatory and
commercial milestone payments, including royalties on future product sales.
About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company
Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option
exists to date. The company therefore concentrates on developing innovative therapies that can extend
patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical
industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the
three business areas, human pharmaceuticals, animal health and biopharmaceuticals. In 2018,
Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2
billion euros corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term
success. The company therefore aims at organic growth from its own resources with simultaneous
openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim
naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in
our annual report: http://annualreport.boehringer-ingelheim.com.
About Trutino Bioscience
Trutino Biosciences is a research-driven biopharmaceutical company with a mission to restore immuno-balance in cancer patients by developing the next generation cytokine therapies that can safely activate tumor-fighting immune cells at the disease site without causing adverse side effects. Trutino’s proprietary On-Demand-Cytokine™ (ODC) platform technology enables the design of therapeutic candidates that can be systemically delivered in an inactive cytokine form and be locally activated
directly at the tumor site, thereby avoiding the extreme toxicity of conventional cytokine therapies, and potentially improving efficacy either as a single agent or in combination with other treatment modalities.
Established in 2018, Trutino is developing an expansive menu of novel ZYTOKINES™ and ZYMOKINES™
derived from its ODC platform that trigger maximal cancer-fighting immune responses only at tumor
sites without the risk of systemic toxicity. The company’s lead product candidate, ODC-IL2, has produced
compelling preclinical data suggesting it is poised to become a best-in-class IL-2 therapy with the
potential of enhanced synergies in combination therapy approaches.
For more information about Trutino Biosciences, please visit www.trutinobio.com and follow us on
For further information, please contact:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
+49 6132 77-90815
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
Biocom’s 10th Annual Global Life Science Partnering Conference, February 25-27 2020, La Jolla, CA
This event is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Industry leaders will debate current trends, companies will showcase their latest technologies.
AACR Annual Meeting, April 24-29 2020, San Diego, CA (Postponed)
Due to technical difficulties, the AACR Annual Business Meeting of Members has been postponed and will be held at a later date.
Executive and scientific leaders from Trutino Biosciences will be attending AACR Annual meeting being held in San Diego. Please check here soon for details regarding our presentation.
38th Annual J.P. Morgan Healthcare Conference, Jan. 13-16 2020, San Francisco, CA
Phillip Kim, CEO and founder of Trutino Biosciences, will be attending the 38th Annual J.P. Morgan Healthcare conference in San Francisco.
If you are interested in scheduling a meeting to learn more about the next generation of cancer immunotherapies that we are developing and the innovative platform technology we are employing, please email firstname.lastname@example.org.